Master Precertification List - Removed Codes For Health Care Providers



November 2025

*This list identifies the codes that required precertification at any time within the last 24 months. The date each code was removed from precertification is also noted. Please reference the current published Master Precertification List for all codes that currently require precertification.

Complete/PHS+ - The most comprehensive care management model that includes all the components of our Preferred level, plus additional digital tools and the highest level of engagement and potential savings.

Preferred - A comprehensive care management model that includes all the components of our existing care management model, including comprehensive outpatient precertification, plus higher intensity of care coordination and more customer engagement opportunities.

Basic Standard - A lower touch care management model that includes many of the components of our existing care management model, such as higher intensity of care coordination and more customer engagement opportunities. Basic Standard has a limited number of outpatient precertification categories (radiation therapy, medical oncology, medical injectables, home infusion therapy and private duty nursing), fewer than our Preferred and Complete solutions.

* Code may be delegated to EviCore for precertification management for certain clients.

Code	Code Description	Precert Effective Date	Precert Removal Date	ACA/IFP Precert Effective Date	Comments	Complete/PHS+ /Preferred	Basic Standard
Revenue Code 0912	Partial hospitalization-less intensive	8/27/2015	12/31/2024			x	
Revenue Code 0913	Partial hospitalization- intensive	8/27/2015	12/31/2024			х	
0071T	Focused ultrasound ablation of uterine leiomyomata, including MR guidance; total leiomyomata volume less than 200 cc of tissue	10/1/2006	4/25/2025			x	x
0072T	Focused ultrasound ablation of uterine leiomyomata, including MR guidance; total leiomyomata volume greater or equal to 200 cc of tissue	10/1/2006	4/25/2025			x	х
0080U	Oncology (lung), mass spectrometric analysis of galectin-3-binding protein and scavenger receptor cysteine-rich type 1 protein M130, with five clinical risk factors (age, smoking status, nodule diameter, nodule-spiculation status and nodule location), utilizing plasma, algorithm reported as a categorical probability of malignancy	1/1/2019	10/17/2025			x	
0118U	Transplantation medicine, quantification of donor-derived cell-free DNA using whole genome next-generation sequencing, plasma, reported as percentage of donor-derived cell-free DNA in the total cell-free DNA	10/1/2019	10/31/2024			x	x
0169U	NUDT15 (nudix hydrolase 15) and TPMT (thiopurine S- methyltransferase) (eg, drug metabolism) gene analysis, common variants	4/1/2020	10/31/2024			х	
0245U	Oncology (thyroid), mutation analysis of 10 genes and 37 RNA fusions and expression of 4 mRNA markers using next-generation sequencing, fine needle aspirate, report includes associated risk of malignancy expressed as a percentage	4/1/2021	10/31/2024			x	
0261U	Oncology (colorectal cancer), image analysis with artificial intelligence assessment of 4 histologic and immunohistochemical features (CD3 and CD8 within tumor-stroma border and tumor core), tissue, reported as immune response and recurrence-risk score	10/1/2021	10/17/2025			x	х
0263T	Intramuscular autologous bone marrow cell therapy, with preparation of harvested cells, multiple injections, one leg, including ultrasound guidance, if performed; complete procedure including unilateral or bilateral bone marrow harvest	7/1/2011	4/25/2025			x	x
0365U	Oncology (bladder), analysis of 10 protein biomarkers (A1AT, ANG, APOE, CA9, IL8, MMP9, MMP10, PAI1, SDC1 and VEGFA) by immunoassays, urine, algorithm reported as a probability of bladder cancer	4/28/2023	10/31/2024			х	
0366U	Oncology (bladder), analysis of 10 protein biomarkers (A1AT, ANG, APOE, CA9, IL8, MMP9, MMP10, PAI1, SDC1 and VEGFA) by immunoassays, urine, algorithm reported as a probability of recurrent bladder cancer	4/28/2023	10/31/2024			x	
0367U	Oncology (bladder), analysis of 10 protein biomarkers (A1AT, ANG, APOE, CA9, IL8, MMP9, MMP10, PAI1, SDC1 and VEGFA) by immunoassays, urine, diagnostic algorithm reported as a risk score for probability of rapid recurrence of recurrent or persistent cancer following transurethral resection	4/28/2023	10/31/2024			x	
0378U	RFC1 (Replication Factor C Subunit 1), Repeat Expansion Variant Analysis By Traditional And Repeat-Primed Pcr, Blood, Saliva, Or Buccal Swab	4/1/2023	4/12/2024			х	
0384U	Nephrology (chronic kidney disease), carboxymethyllysine, methylglyoxal hydroimidazolone, and carboxyethyl lysine by liquid chromatography with tandem mass spectrometry (LC-MS/MS) and HbA1c and estimated glomerular filtration rate (GFR), with risk score reported for predictive progression to high-stage kidney disease	4/28/2023	10/17/2025			x	x

[&]quot;Cigna Companies" refers to operating subsidiaries of Cigna Corporation. All products and services are provided exclusively by or through such operating subsidiaries, including Cigna Health and Life Insurance Company, Connecticut General Life Insurance Company, Evernorth Behavioral Health, Inc., Cigna Health Management, Inc., and HMO or service company subsidiaries of Cigna Health Corporation. © 2025 Cigna.

Code	Code Description	Precert Effective Date	Precert Removal Date	ACA/IFP Precert Effective Date	Comments	Complete/PHS+ /Preferred	Basic Standard
0385U	Nephrology (chronic kidney disease), apolipoprotein A4 (ApoA4), CD5 antigen-like (CD5L), and insulin-like growth factor binding protein 3 (IGFBP3) by enzyme-linked immunoassay (ELISA), plasma, algorithm combining results with HDL, estimated glomerular filtration rate (GFR) and clinical data reported as a risk score for developing diabetic kidney disease	4/28/2023	10/17/2025			х	х
0424T	Insertion or replacement of neurostimulator system for treatment of central sleep apnea; complete system (transvenous placement of right or left stimulation lead, sensing lead, implantable pulse generator)	1/1/2016	12/31/2023		Code deleted 12/31/2023	x	x
0443U	Neurofilament light chain (NfL), ultra-sensitive immunoassay, serum or cerebrospinal fluid	4/1/2024	3/28/2025			х	
0445U	β-amyloid (Abeta42) and phospho tau (181P) (pTau181), electrochemiluminescent immunoassay (ECLIA), cerebral spinal fluid, ratio reported as positive or negative for amyloid pathology	4/1/2024	10/17/2025			x	x
0446T	Creation of subcutaneous pocket with insertion of implantable interstitial glucose sensor, including system activation and patient training	1/1/2017	12/6/2024			х	х
0448T	Removal of implantable interstitial glucose sensor with creation of subcutaneous pocket at different anatomic site and insertion of new implantable sensor, including system activation	1/1/2017	12/6/2024			x	x
0448U*	Oncology (lung and colon cancer), DNA, qualitative, next-generation sequencing detection of single-nucleotide variants and deletions in EGFR and KRAS genes, formalin-fixed paraffin-embedded (FFPE) solid tumor samples, reported as presence or absence of targeted mutation(s), with recommended therapeutic options	4/1/2024	12/31/2024		Code deleted 12/31/2024	x	x
0449U	Carrier screening for severe inherited conditions (eg, cystic fibrosis, spinal muscular atrophy, beta hemoglobinopathies [including sickle cell disease], alpha thalassemia), regardless of race or self-identified ancestry, genomic sequence analysis panel, must include analysis of 5 genes (CFTR, SMN1, HBB, HBA1, HBA2)	4/1/2024	6/27/2025			x	
0457U	Perfluoroalkyl substances (PFAS) (eg, perfluorooctanoic acid, perfluorooctane sulfonic acid), 9 PFAS compounds by LC-MS/MS, plasma or serum, quantitative	7/1/2024	3/28/2025			х	
0458U	Oncology (breast cancer), S100A8 and S100A9, by enzyme-linked immunosorbent assay (ELISA), tear fluid with age, algorithm reported as a risk score	9/27/2024	10/17/2025			х	х
0459U	$\beta\text{-amyloid}$ (Abeta42) and total tau (tTau), electrochemiluminescent immunoassay (ECLIA), cerebral spinal fluid, ratio reported as positive or negative for amyloid pathology	7/1/2024	10/17/2025			x	x
0464U	Oncology (colorectal) screening, quantitative real-time target and signal amplification, methylated DNA markers, including LASS4, LRRC4 and PPP2RSC, a reference marker ZDHHC1, and a protein marker (fecal hemoglobin), utilizing stool, algorithm reported as a positive or negative result	7/1/2024	2/28/2025			х	
0479U	Tau, phosphorylated, pTau217	10/1/2024	10/31/2024			x	x
0482U	Obstetrics (preeclampsia), biochemical assay of soluble fmslike tyrosine kinase 1 (sFlt-1) and placental growth factor (PIGF), serum, ratio reported for sFlt1/PIGF, with risk of progression for preeclampsia with severe features within 2 weeks	10/1/2024	10/31/2024			х	х
0490U	Oncology (cutaneous or uveal melanoma), circulating tumor cell selection, morphological characterization and enumeration based on differential CD146, high molecular-weight melanoma-associated antigen, CD34 and CD45 protein biomarkers, peripheral blood	10/1/2024	10/17/2025			x	

[&]quot;Cigna Companies" refers to operating subsidiaries of Cigna Corporation. All products and services are provided exclusively by or through such operating subsidiaries, including Cigna Health and Life Insurance Company, Connecticut General Life Insurance Company, Evernorth Behavioral Health, Inc., Cigna Health Management, Inc., and HMO or service company subsidiaries of Cigna Health Corporation. © 2025 Cigna.

Code	Code Description	Precert Effective Date	Precert Removal Date	ACA/IFP Precert Effective Date	Comments	Complete/PHS+ /Preferred	Basic Standard
0491U	Oncology (solid tumor), circulating tumor cell selection, morphological characterization and enumeration based on differential epithelial cell adhesion molecule (EpCAM), cytokeratins 8, 18, and 19, CD45 protein biomarkers, and quantification of estrogen receptor (ER) protein biomarker-expressing cells, peripheral blood	10/1/2024	10/17/2025			x	x
0492U	Oncology (solid tumor), circulating tumor cell selection, morphological characterization and enumeration based on differential epithelial cell adhesion molecule (EpCAM), cytokeratins 8, 18, and 19, CD45 protein biomarkers, and quantification of PD-L1 protein biomarker-expressing cells, peripheral blood	10/1/2024	10/17/2025			x	x
0503U	Neurology (Alzheimer disease), beta amyloid (Aβ40, Aβ42, Aβ42/40 ratio) and tau-protein (ptau217, np-tau217, ptau217/nptau217 ratio), blood, immunoprecipitation with quantitation by liquid chromatography with tandem mass spectrometry (LC-MS/MS), algorithm score reported as likelihood of positive or negative for amyloid plaques	10/1/2024	10/31/2024			x	x
0511U	Oncology (solid tumor), tumor cell culture in 3D microenvironment, 36 or more drug panel, reported as tumor-response prediction for each drug	10/1/2024	10/31/2024			x	х
0514U	Gastroenterology (irritable bowel disease [IBD]), immunoassay for quantitative determination of adalimumab (ADL) levels in venous serum in patients undergoing adalimumab therapy, results reported as a numerical value as micrograms per milliliter (μg/mL)	10/1/2024	10/31/2024			x	x
0515U	Gastroenterology (irritable bowel disease [IBD]), immunoassay for quantitative determination of infliximab (IFX) levels in venous serum in patients undergoing infliximab therapy, results reported as a numerical value as micrograms per milliliter (µg/mL)	10/1/2024	10/31/2024			x	х
0517U	Therapeutic drug monitoring, 80 or more psychoactive drugs or substances, LC-MS/MS, plasma, qualitative and quantitative therapeutic minimally and maximally effective dose of prescribed and non-prescribed medications	10/1/2024	10/31/2024			x	х
0518U	Therapeutic drug monitoring, 90 or more pain and mental health drugs or substances, LC-MS/MS, plasma, qualitative and quantitative therapeutic minimally effective range of prescribed and non-prescribed medications	10/1/2024	10/31/2024			x	x
0519U	Therapeutic drug monitoring, medications specific to pain, depression, and anxiety, LCMS/MS, plasma, 110 or more drugs or substances, qualitative and quantitative therapeutic minimally effective range of prescribed, non-prescribed, and illicit medications in circulation	10/1/2024	10/31/2024			x	x
0520U	Therapeutic drug monitoring, 200 or more drugs or substances, LCMS/MS, plasma, qualitative and quantitative therapeutic minimally effective range of prescribed and non-prescribed medications	10/1/2024	10/31/2024			x	x
0537T	Chimeric antigen receptor T-cell (CAR-T) therapy; harvesting of blood- derived T lymphocytes for development of genetically modified autologous CAR-T cells, per day	1/1/2019	12/31/2024		Code deleted 12/31/2024	х	x
0538T	Chimeric antigen receptor T-cell (CAR-T) therapy; preparation of blood-derived T lymphocytes for transportation (eg, cryopreservation, storage)	1/1/2019	12/31/2024		Code deleted 12/31/2024	х	х
0539T	Chimeric antigen receptor T-cell (CAR-T) therapy; receipt and preparation of CAR-T cells for administration	1/1/2019	12/31/2024		Code deleted 12/31/2024	х	х
0540T	Chimeric antigen receptor T-cell (CAR-T) therapy; CAR-T cell administration, autologous	1/1/2019	12/31/2024		Code deleted 12/31/2024	х	х
0558U	Oncology (colorectal), quantitative enzyme-linked immunosorbent assay (ELISA) for secreted colorectal cancer protein marker (BF7 antigen), using serum, result reported as indicative of response/no response to therapy or disease progression/regression	7/1/2025	10/17/2025			x	x

[&]quot;Cigna Companies" refers to operating subsidiaries of Cigna Corporation. All products and services are provided exclusively by or through such operating subsidiaries, including Cigna Health and Life Insurance Company, Connecticut General Life Insurance Company, Evernorth Behavioral Health, Inc., Cigna Health Management, Inc., and HMO or service company subsidiaries of Cigna Health Corporation. © 2025 Cigna.

Code	Code Description	Precert Effective Date	Precert Removal Date	ACA/IFP Precert Effective Date	Comments	Complete/PHS+ /Preferred	Basic Standard
0559U	Oncology (breast), quantitative enzyme-linked immunosorbent assay (ELISA) for secreted breast cancer protein marker (BF9 antigen), serum, result reported as indicative of response/no response to therapy or disease progression/regression	7/1/2025	10/17/2025			x	x
0568U	Neurology (dementia), beta amyloid (Aβ40, Aβ42, Aβ42/40 ratio), tau- protein phosphorylated at residue (eg, pTau217), neurofilament light chain (NfL), and glial fibrillary acidic protein (GFAP), by ultra-high sensitivity molecule array detection, plasma, algorithm reported as positive, intermediate, or negative for Alzheimer pathology	7/1/2025	10/17/2025			x	x
0574U	Mycobacterium tuberculosis, culture filtrate protein–10-kDa (CFP-10), serum or plasma, liquid chromatography mass spectrometry (LC-MS)	7/1/2025	10/17/2025			x	x
0616T	Insertion of iris prosthesis, including suture fixation and repair or removal of iris, when performed; without removal of crystalline lens or intraocular lens, without insertion of intraocular lens	7/1/2020	12/31/2024		Code deleted 12/31/2024	x	
0617T	Insertion of iris prosthesis, including suture fixation and repair or removal of iris, when performed; with removal of crystalline lens and insertion of intraocular lens	7/1/2020	12/31/2024		Code deleted 12/31/2024	х	
0618T	Insertion of iris prosthesis, including suture fixation and repair or removal of iris, when performed; with secondary intraocular lens placement or intraocular lens exchange	7/1/2020	12/31/2024		Code deleted 12/31/2024	x	
0715T	Percutaneous transluminal coronary lithotripsy	7/1/2022	12/31/2023		Code deleted 12/31/2023	x	х
0775T	Arthrodesis, sacroiliac joint, percutaneous, with image guidance, includes placement of intra-articular implant(s) (eg, bone allograft[s], synthetic device[s])	1/1/2023	12/31/2023		Code deleted 12/31/2023	x	
0795T*	Transcatheter insertion of permanent dual-chamber leadless pacemaker, including imaging guidance (eg, fluoroscopy, venous ultrasound, right atrial angiography, right ventriculography, femoral venography) and device evaluation (eg, interrogation or programming), when performed; complete system (ie, right atrial and right ventricular pacemaker components)	7/1/2023	5/30/2025			x	
0796T*	Transcatheter insertion of permanent dual-chamber leadless pacemaker, including imaging guidance (eg, fluoroscopy, venous ultrasound, right atrial angiography, right ventriculography, femoral venography) and device evaluation (eg, interrogation or programming), when performed; right atrial pacemaker component (when an existing right ventricular single leadless pacemaker exists to create a dual-chamber leadless pacemaker system)	7/1/2023	5/30/2025			x	
0797T*	Transcatheter insertion of permanent dual-chamber leadless pacemaker, including imaging guidance (eg, fluoroscopy, venous ultrasound, right atrial angiography, right ventriculography, femoral venography) and device evaluation (eg, interrogation or programming), when performed; right ventricular pacemaker component (when part of a dual-chamber leadless pacemaker system)	7/1/2023	5/30/2025			x	
0801T	Transcatheter removal and replacement of permanent dual-chamber leadless pacemaker, including imaging guidance (eg, fluoroscopy, venous ultrasound, right atrial angiography, right ventriculography, femoral venography) and device evaluation (eg, interrogation or programming), when performed; dual-chamber system (ie, right atrial and right ventricular pacemaker components)	7/1/2023	2/28/2025			x	
0802T	Transcatheter removal and replacement of permanent dual-chamber leadless pacemaker, including imaging guidance (eg, fluoroscopy, venous ultrasound, right atrial angiography, right ventriculography, femoral venography) and device evaluation (eg, interrogation or programming), when performed; right atrial pacemaker component	7/1/2023	2/28/2025			x	

[&]quot;Cigna Companies" refers to operating subsidiaries of Cigna Corporation. All products and services are provided exclusively by or through such operating subsidiaries, including Cigna Health and Life Insurance Company, Connecticut General Life Insurance Company, Evernorth Behavioral Health, Inc., Cigna Health Management, Inc., and HMO or service company subsidiaries of Cigna Health Corporation. © 2025 Cigna.

Code	Code Description	Precert Effective Date	Precert Removal Date	ACA/IFP Precert Effective Date	Comments	Complete/PHS+ /Preferred	Basic Standard
0803T	Transcatheter removal and replacement of permanent dual-chamber leadless pacemaker, including imaging guidance (eg, fluoroscopy, venous ultrasound, right atrial angiography, right ventriculography, femoral venography) and device evaluation (eg, interrogation or programming), when performed; right ventricular pacemaker component (when part of a dual-chamber leadless pacemaker system)	1/1/2024	2/28/2025			x	
0809T	Arthrodesis, sacroiliac joint, percutaneous or minimally invasive (indirect visualization), with image guidance, placement of transfixing device(s) and intraarticular implant(s), including allograft or synthetic device(s)	7/1/2023	12/31/2023		Code deleted 12/31/2023	х	х
0823T*	Transcatheter insertion of permanent single-chamber leadless pacemaker, right atrial, including imaging guidance (eg, fluoroscopy, venous ultrasound, right atrial angiography and/or right ventriculography, femoral venography, cavography) and device evaluation (eg, interrogation or programming), when performed	1/1/2024	5/30/2025			x	
0824T*	Transcatheter removal of permanent single-chamber leadless pacemaker, right atrial, including imaging guidance (eg, fluoroscopy, venous ultrasound, right atrial angiography and/or right ventriculography, femoral venography, cavography), when performed	1/1/2024	5/30/2025			x	
0825T*	Transcatheter removal and replacement of permanent single-chamber leadless pacemaker, right atrial, including imaging guidance (eg, fluoroscopy, venous ultrasound, right atrial angiography and/or right ventriculography, femoral venography, cavography) and device evaluation (eg, interrogation or programming), when performed	1/1/2024	5/30/2025			x	
0898T	Noninvasive prostate cancer estimation map, derived from augmentative analysis of image-guided fusion biopsy and pathology, including visualization of margin volume and location, with margin determination and physician interpretation and report	7/1/2024	2/28/2025			x	
0977T	Upper gastrointestinal blood detection, sensor capsule, with interpretation and report	7/1/2025	9/12/2025			x	x
15819	Cervicoplasty	10/1/2006	12/31/2024		Code deleted 12/31/2024	x	х
19105	Ablation, cryosurgical, of fibroadenoma, including ultrasound guidance, each fibroadenoma	1/22/2007	12/31/2024			х	x
21032	Excision of maxillary torus palatinus	10/1/2006	2/28/2025			х	
21181	Reconstruction by contouring of benign tumor of cranial bones (eg, fibrous dysplasia), extracranial	8/19/2013	2/28/2025			x	x
21182	Reconstruction of orbital walls, rims, forehead, nasoethmoid complex following intra- and extracranial excision of benign tumor of cranial bone (eg, fibrous dysplasia), with multiple autografts (includes obtaining grafts); total area of bone grafting less than 40 sq cm	10/1/2006	2/28/2025			x	х
21280	Medial canthopexy	10/1/2006	2/28/2025			х	х
21282	Lateral canthopexy	10/1/2006	2/28/2025			x	х
21325	Open treatment of nasal fracture; uncomplicated	2/18/2013	10/17/2025			x	x
21347	Open treatment of nasomaxillary complex fracture (LeFort II type); requiring multiple open approaches	10/1/2006	2/28/2025			х	
21348	Open treatment of nasomaxillary complex fracture (LeFort II type); with bone grafting (includes obtaining graft)	10/1/2006	2/28/2025			х	
21432	Open treatment of craniofacial separation (LeFort III type); with wiring and/or internal fixation	10/1/2006	2/28/2025			х	
21433	Open treatment of craniofacial separation (LeFort III type); complicated (eg, comminuted or involving cranial nerve foramina), multiple surgical approaches	10/1/2006	2/28/2025			х	

[&]quot;Cigna Companies" refers to operating subsidiaries of Cigna Corporation. All products and services are provided exclusively by or through such operating subsidiaries, including Cigna Health and Life Insurance Company, Connecticut General Life Insurance Company, Evernorth Behavioral Health, Inc., Cigna Health Management, Inc., and HMO or service company subsidiaries of Cigna Health Corporation. © 2025 Cigna.

Code	Code Description	Precert Effective Date	Precert Removal Date	ACA/IFP Precert Effective Date	Comments	Complete/PHS+ /Preferred	Basic Standard
21435	Open treatment of craniofacial separation (LeFort III type); complicated, utilizing internal and/or external fixation techniques (eg, head cap, halo device, and/or intermaxillary fixation)	10/1/2006	2/28/2025			x	
21436	Open treatment of craniofacial separation (LeFort III type); complicated, multiple surgical approaches, internal fixation, with bone grafting (includes obtaining graft)	10/1/2006	2/28/2025			x	
22102	Partial excision of posterior vertebral component (eg, spinous process, lamina or facet) for intrinsic bony lesion, single vertebral segment; lumbar	10/1/2006	12/31/2024			х	
22325	Open treatment and/or reduction of vertebral fracture(s) and/or dislocation(s), posterior approach, one fractured vertebrae or dislocated segment; lumbar	8/23/2019	10/31/2024			x	
22326	Open treatment and/or reduction of vertebral fracture(s) and/or dislocation(s), posterior approach, 1 fractured vertebra or dislocated segment; cervical	8/23/2019	10/31/2024			x	
22328	Open treatment and/or reduction of vertebral fracture(s) and/or dislocation(s), posterior approach, 1 fractured vertebra or dislocated segment; each additional fractured vertebra or dislocated segment	8/23/2019	10/31/2024			x	
26341	Manipulation, palmar fascial cord (ie, Dupuytren's cord), post enzyme injection (eg, collagenase), single cord	8/6/2012	2/28/2025			х	
27197	Closed treatment of posterior pelvic ring fracture(s), dislocation(s), diastasis or subluxation of the ilium, sacroiliac joint, and/or sacrum, with or without anterior pelvic ring fracture(s) and/or dislocation(s) of the pubic symphysis and/or superior/inferior rami, unilateral or bilateral; without manipulation	1/1/2017	7/25/2025			x	
28446	Open osteochondral autograft, talus (includes obtaining graft[s])	1/1/2008	4/25/2025			х	х
31643*	Bronchoscopy, rigid or flexible, including fluoroscopic guidance, when performed; with placement of catheter(s) for intracavitary radioelement application	8/1/2012	5/30/2025			х	х
31647	Bronchoscopy, rigid or flexible, including fluoroscopic guidance, when performed; with balloon occlusion, when performed, assessment of air leak, airway sizing, and insertion of bronchial valve(s), initial lobe	1/1/2013	2/28/2025			x	
31660	Bronchoscopy, rigid or flexible, including fluoroscopic guidance, when performed; with bronchial thermoplasty, 1 lobe	1/1/2013	2/28/2025			х	х
31661	Bronchoscopy, rigid or flexible, including fluoroscopic guidance, when performed; with bronchial thermoplasty, 2 or more lobes	1/1/2013	2/28/2025			х	х
33206*	Insertion of new or replacement of permanent pacemaker with transvenous electrode(s); atrial	2/1/2021	5/30/2025			х	
33207*	Insertion of new or replacement of permanent pacemaker with transvenous electrode(s); ventricular	2/1/2021	5/30/2025			х	
33208*	Insertion of new or replacement of permanent pacemaker with transvenous electrode(s); atrial and ventricular	2/1/2021	5/30/2025			х	
33274*	Transcatheter insertion or replacement of permanent leadless pacemaker, right ventricular, including imaging guidance (eg, fluoroscopy, venous ultrasound, ventriculography, femoral venography) and device evaluation (eg, interrogation or programming), when performed	1/1/2019	5/30/2025			x	
34717	Endovascular repair of iliac artery at the time of aorto-iliac artery endograft placement by deployment of an iliac branched endograft including pre-procedure sizing and device selection, all ipsilateral selective iliac artery catheterization(s), all associated radiological supervision and interpretation, and all endograft extension(s) proximally to the aortic bifurcation and distally in the internal iliac, external iliac, and common femoral artery(ies), and treatment zone angioplasty/stenting, when performed, for rupture or other than rupture (eg, for aneurysm, pseudoaneurysm, dissection, arteriovenous malformation, penetrating ulcer, traumatic disruption), unilateral	1/1/2020	10/31/2024			x	x

[&]quot;Cigna Companies" refers to operating subsidiaries of Cigna Corporation. All products and services are provided exclusively by or through such operating subsidiaries, including Cigna Health and Life Insurance Company, Connecticut General Life Insurance Company, Evernorth Behavioral Health, Inc., Cigna Health Management, Inc., and HMO or service company subsidiaries of Cigna Health Corporation. © 2025 Cigna.

Code	Code Description	Precert Effective Date	Precert Removal Date	ACA/IFP Precert Effective Date	Comments	Complete/PHS+ /Preferred	Basic Standard
36299	Unlisted procedure, vascular injection	10/1/2006	5/31/2024			х	x
41820	Gingivectomy, excision gingiva, each quadrant	10/1/2006	2/28/2025			х	
42950	Pharyngoplasty (plastic or reconstructive operation on pharynx)	10/1/2006	12/31/2024			х	
43200*	Esophagoscopy, flexible, transoral; diagnostic, including collection of specimen(s) by brushing or washing, when performed	1/1/2022	5/30/2025			х	
43201*	Esophagoscopy, flexible, transoral; with directed submucosal injection(s), any substance	1/1/2022	5/30/2025			х	
43202*	Esophagoscopy, flexible, transoral; with biopsy, single or multiple	1/1/2022	5/30/2025			х	
43204*	Esophagoscopy, flexible, transoral; with injection sclerosis of esophageal varices	1/1/2022	5/30/2025			x	
43205*	Esophagoscopy, flexible, transoral; with band ligation of esophageal varices	1/1/2022	5/30/2025			х	
43206*	Esophagoscopy, flexible, transoral; with optical endomicroscopy	1/1/2022	5/30/2025			х	
43211*	Esophagoscopy, flexible, transoral; with endoscopic mucosal resection	1/1/2022	5/30/2025			х	
43212*	Esophagoscopy, flexible, transoral; with placement of endoscopic stent (includes pre- and post-dilation and guide wire passage, when performed)	1/1/2022	5/30/2025			x	
43213*	Esophagoscopy, flexible, transoral; with dilation of esophagus, by balloon or dilator, retrograde (includes fluoroscopic guidance, when performed)	1/1/2022	5/30/2025			х	
43214*	Esophagoscopy, flexible, transoral; with dilation of esophagus with balloon (30 mm diameter or larger) (includes fluoroscopic guidance, when performed)	1/1/2022	5/30/2025			х	
43215*	Esophagoscopy, flexible, transoral; with removal of foreign body(s)	1/1/2022	5/30/2025			x	
43216*	Esophagoscopy, flexible, transoral; with removal of tumor(s), polyp(s), or other lesion(s) by hot biopsy forceps	1/1/2022	5/30/2025			х	
43217*	Esophagoscopy, flexible, transoral; with removal of tumor(s), polyp(s), or other lesion(s) by snare technique	1/1/2022	5/30/2025			х	
43220*	Esophagoscopy, flexible, transoral; with transendoscopic balloon dilation (less than 30 mm diameter)	1/1/2022	5/30/2025			x	
43226*	Esophagoscopy, flexible, transoral; with insertion of guide wire followed by passage of dilator(s) over guide wire	1/1/2022	5/30/2025			х	
43227*	Esophagoscopy, flexible, transoral; with control of bleeding, any method	1/1/2022	5/30/2025			х	
43229*	Esophagoscopy, flexible, transoral; with ablation of tumor(s), polyp(s), or other lesion(s) (includes pre- and post-dilation and guide wire passage, when performed)	1/1/2022	5/30/2025			х	
43246*	Esophagogastroduodenoscopy, flexible, transoral; with directed placement of percutaneous gastrostomy tube	1/1/2022	10/17/2025			х	
43648	Laparoscopy, surgical; revision or removal of gastric neurostimulator electrodes, antrum	1/22/2007	2/28/2025			x	
50380	Renal autotransplantation, reimplantation of kidney	10/1/2006	2/28/2025			х	
54408	Repair of component(s) of a multi-component, inflatable penile prosthesis	10/1/2006	9/12/2025			х	
54410	Removal and replacement of all component(s) of a multi-component, inflatable penile prosthesis at the same operative session	10/1/2006	9/12/2025			х	
54416	Removal and replacement of non-inflatable (semi-rigid) or inflatable (self-contained) penile prosthesis at the same operative session	10/1/2006	9/12/2025			x	
61888	Revision or removal of cranial neurostimulator pulse generator or receiver	2/18/2013	12/31/2024			х	
61891	Revision or replacement of skull-mounted cranial neurostimulator pulse generator or receiver with connection to depth and/or cortical strip electrode array(s)	1/1/2024	12/31/2024			х	

[&]quot;Cigna Companies" refers to operating subsidiaries of Cigna Corporation. All products and services are provided exclusively by or through such operating subsidiaries, including Cigna Health and Life Insurance Company, Connecticut General Life Insurance Company, Evernorth Behavioral Health, Inc., Cigna Health Management, Inc., and HMO or service company subsidiaries of Cigna Health Corporation. © 2025 Cigna.

Code	Code Description	Precert Effective Date	Precert Removal Date	ACA/IFP Precert Effective Date	Comments	Complete/PHS+ /Preferred	Basic Standard
63011	Laminectomy with exploration and/or decompression of spinal cord and/or cauda equina, without facetectomy, foraminotomy or discectomy (eg, spinal stenosis), 1 or 2 vertebral segments; sacral	1/1/2024	12/31/2024			x	
64598	Revision or removal of neurostimulator electrode array, peripheral nerve, with integrated neurostimulator	1/1/2024	5/31/2024			х	
64620	Destruction by neurolytic agent, intercostal nerve	1/1/2016	12/31/2024			х	
64804	Sympathectomy, cervicothoracic	10/1/2006	2/28/2025			х	
66184	Revision of aqueous shunt to extraocular equatorial plate reservoir; without graft	1/1/2015	12/31/2024			х	
70450*	Computed tomography, head or brain; without contrast material	10/1/2006	5/30/2025			х	
70460*	Computed tomography, head or brain; with contrast material(s)	10/1/2006	5/30/2025			х	
70470*	Computed tomography, head or brain; without contrast material, followed by contrast material(s) and further sections	10/1/2006	5/30/2025			х	
70480*	Computed tomography, orbit, sella, or posterior fossa or outer, middle, or inner ear; without contrast material	10/1/2006	5/30/2025			х	
70481*	Computed tomography, orbit, sella, or posterior fossa or outer, middle, or inner ear; with contrast material(s)	10/1/2006	5/30/2025			x	
70482*	Computed tomography, orbit, sella, or posterior fossa or outer, middle, or inner ear; without contrast material, followed by contrast material(s) and further sections	10/1/2006	5/30/2025			х	
70486*	Computed tomography, maxillofacial area; without contrast material	10/1/2006	5/30/2025			х	
70487*	Computed tomography, maxillofacial area; with contrast material(s)	10/1/2006	5/30/2025			х	
70488*	Computed tomography, maxillofacial area; without contrast material, followed by contrast material(s) and further sections	10/1/2006	5/30/2025			х	
70496*	Computed tomographic angiography, head, with contrast material(s), including noncontrast images, if performed, and image postprocessing	10/1/2006	5/30/2025			x	
70544*	Magnetic resonance angiography, head; without contrast material(s)	10/1/2006	5/30/2025			х	
70545*	Magnetic resonance angiography, head; with contrast material(s)	10/1/2006	5/30/2025			х	
70546*	Magnetic resonance angiography, head; without contrast material(s), followed by contrast material(s) and further sequences	10/1/2006	5/30/2025			x	
70551*	Magnetic resonance (eg, proton) imaging, brain (including brain stem); without contrast material	10/1/2006	5/30/2025			х	
70552*	Magnetic resonance (eg, proton) imaging, brain (including brain stem); with contrast material(s)	10/1/2006	5/30/2025			х	
70553*	Magnetic resonance (eg, proton) imaging, brain (including brain stem); without contrast material, followed by contrast material(s) and further sequences	10/1/2006	5/30/2025			х	
70554*	Magnetic resonance imaging, brain, functional MRI; including test selection and administration of repetitive body part movement and/or visual stimulation, not requiring physician or psychologist administration	1/22/2007	5/30/2025			x	
70555*	Magnetic resonance imaging, brain, functional MRI; requiring physician or psychologist administration of entire neurofunctional testing	1/22/2007	5/30/2025			х	
71271*	Computed tomography, thorax, low dose for lung cancer screening, without contrast material(s)	1/1/2021	2/28/2025			х	
74261*	Computed tomographic (CT) colonography, diagnostic, including image postprocessing; without contrast material	1/1/2010	5/30/2025			х	
74262*	Computed tomographic (CT) colonography, diagnostic, including image postprocessing; with contrast material(s) including non-contrast images, if performed	1/1/2010	5/30/2025			x	
74263*	Computed tomographic (CT) colonography, screening, including image postprocessing	1/1/2010	5/30/2025			х	

[&]quot;Cigna Companies" refers to operating subsidiaries of Cigna Corporation. All products and services are provided exclusively by or through such operating subsidiaries, including Cigna Health and Life Insurance Company, Connecticut General Life Insurance Company, Evernorth Behavioral Health, Inc., Cigna Health Management, Inc., and HMO or service company subsidiaries of Cigna Health Corporation. © 2025 Cigna.

Code	Code Description	Precert Effective Date	Precert Removal Date	ACA/IFP Precert Effective Date	Comments	Complete/PHS+ /Preferred	Basic Standard
75557*	Cardiac magnetic resonance imaging for morphology and function without contrast material;	1/1/2008	5/30/2025			х	
75559*	Cardiac magnetic resonance imaging for morphology and function without contrast material; with stress imaging	10/1/2006	5/30/2025			x	
75561*	Cardiac magnetic resonance imaging for morphology and function without contrast material(s), followed by contrast material(s) and further sequences;	1/1/2008	5/30/2025			x	
75563*	Cardiac magnetic resonance imaging for morphology and function without contrast material(s), followed by contrast material(s) and further sequences; with stress imaging	1/1/2008	5/30/2025			x	
75565*	Cardiac magnetic resonance imaging for velocity flow mapping	1/1/2010	5/30/2025			x	
75571*	Computed tomography, heart, without contrast material, with quantitative evaluation of coronary calcium	1/1/2010	5/30/2025			х	
75572*	Computed tomography, heart, with contrast material, for evaluation of cardiac structure and morphology (including 3D image postprocessing, assessment of cardiac function, and evaluation of venous structures, if performed)	1/1/2010	5/30/2025			x	
75573*	Computed tomography, heart, with contrast material, for evaluation of cardiac structure and morphology in the setting of congenital heart disease (including 3D image postprocessing, assessment of left ventricular [LV] cardiac function, right ventricular [RV] structure and function and evaluation of vascular structures, if performed)	1/1/2010	5/30/2025			x	
75580	Noninvasive estimate of coronary fractional flow reserve (FFR) derived from augmentative software analysis of the data set from a coronary computed tomography angiography, with interpretation and report by a physician or other qualified health care professional	1/1/2024	3/8/2024			x	
76380*	Computed tomography, limited or localized follow-up study	10/1/2006	5/30/2025			x	
77011	Computed tomography guidance for stereotactic localization	8/1/2012	12/31/2024			х	
77078*	Computed tomography, bone mineral density study, 1 or more sites, axial skeleton (eq, hips, pelvis, spine)	10/1/2006	2/28/2025			х	
77600*	Hyperthermia, externally generated; superficial (ie, heating to a depth of 4 cm or less)	8/1/2012	5/30/2025			х	x
77605*	Hyperthermia, externally generated; deep (ie, heating to depths greater than 4 cm)	8/1/2012	5/30/2025			х	х
77610*	Hyperthermia generated by interstitial probe(s); 5 or fewer interstitial applicators	8/1/2012	5/30/2025			х	х
77615*	Hyperthermia generated by interstitial probe(s); more than 5 interstitial applicators	8/1/2012	5/30/2025			х	х
77620*	Hyperthermia generated by intracavitary probe(s)	8/1/2012	5/30/2025			x	х
78451*	Myocardial perfusion imaging, tomographic (SPECT) (including attenuation correction, qualitative or quantitative wall motion, ejection fraction by first pass or gated technique, additional quantification, when performed); single study, at rest or stress (exercise or pharmacologic)	7/1/2011	5/30/2025			x	
78452*	Myocardial perfusion imaging, tomographic (SPECT) (including attenuation correction, qualitative or quantitative wall motion, ejection fraction by first pass or gated technique, additional quantification, when performed); multiple studies, at rest and/or stress (exercise or pharmacologic) and/or redistribution and/or rest reinjection	7/1/2011	5/30/2025			x	
78453*	Myocardial perfusion imaging, planar (including qualitative or quantitative wall motion, ejection fraction by first pass or gated technique, additional quantification, when performed); single study, at rest or stress (exercise or pharmacologic)	7/1/2011	5/30/2025			x	

[&]quot;Cigna Companies" refers to operating subsidiaries of Cigna Corporation. All products and services are provided exclusively by or through such operating subsidiaries, including Cigna Health and Life Insurance Company, Connecticut General Life Insurance Company, Evernorth Behavioral Health, Inc., Cigna Health Management, Inc., and HMO or service company subsidiaries of Cigna Health Corporation. © 2025 Cigna.

Code	Code Description	Precert Effective Date	Precert Removal Date	ACA/IFP Precert Effective Date	Comments	Complete/PHS+ /Preferred	Basic Standard
78454*	Myocardial perfusion imaging, planar (including qualitative or quantitative wall motion, ejection fraction by first pass or gated technique, additional quantification, when performed); multiple studies, at rest and/or stress (exercise or pharmacologic) and/or redistribution and/or rest reinjection	7/1/2011	5/30/2025			x	
78456	Acute venous thrombosis imaging, peptide	8/17/2009	2/28/2025			x	x
78466*	Myocardial imaging, infarct avid, planar; qualitative or quantitative	7/1/2011	5/30/2025			х	
78468*	Myocardial imaging, infarct avid, planar; with ejection fraction by first pass technique	7/1/2011	5/30/2025			х	
78469*	Myocardial imaging, infarct avid, planar; tomographic SPECT with or without quantification	7/1/2011	5/30/2025			х	
78472*	Cardiac blood pool imaging, gated equilibrium; planar, single study at rest or stress (exercise and/or pharmacologic), wall motion study plus ejection fraction, with or without additional quantitative processing	7/1/2011	5/30/2025			х	
78473*	Cardiac blood pool imaging, gated equilibrium; multiple studies, wall motion study plus ejection fraction, at rest and stress (exercise and/or pharmacologic), with or without additional quantification	7/1/2011	5/30/2025			x	
78481*	Cardiac blood pool imaging (planar), first pass technique; single study, at rest or with stress (exercise and/or pharmacologic), wall motion study plus ejection fraction, with or without quantification	7/1/2011	5/30/2025			x	
78483*	Cardiac blood pool imaging (planar), first pass technique; multiple studies, at rest and with stress (exercise and/or pharmacologic), wall motion study plus ejection fraction, with or without quantification	7/1/2011	5/30/2025			x	
78494*	Cardiac blood pool imaging, gated equilibrium, SPECT, at rest, wall motion study plus ejection fraction, with or without quantitative processing	7/1/2011	5/30/2025			х	
78496*	Cardiac blood pool imaging, gated equilibrium, single study, at rest, with right ventricular ejection fraction by first pass technique	7/1/2011	5/30/2025			x	
78499*	Unlisted cardiovascular procedure, diagnostic nuclear medicine	10/1/2006	5/30/2025			x	
81210	BRAF Gene	9/1/2013	4/12/2024			х	
81233	BTK Gene Common Variants	1/1/2019	4/12/2024			x	
81235	EGFR (epidermal growth factor receptor) (eg, non-small cell lung cancer) gene analysis, common variants (eg, exon 19 LREA deletion, L858R, T790M, G719A, G719S, L861Q)	1/1/2013	10/31/2024			х	
81288	MLH1 Gene	1/1/2015	4/12/2024			x	
81309	PIK3CA Gene Trgt Seq Alys	1/1/2020	4/12/2024			x	
81325	PMP22 (peripheral myelin protein 22) (eg, Charcot-Marie-Tooth, hereditary neuropathy with liability to pressure palsies) gene analysis; full sequence analysis	1/1/2013	10/31/2024			х	
81326	PMP22 (peripheral myelin protein 22) (eg, Charcot-Marie-Tooth, hereditary neuropathy with liability to pressure palsies) gene analysis; known familial variant	1/1/2013	10/31/2024			х	
81328	SLCO1B1 (solute carrier organic anion transporter family, member 1B1) (eg, adverse drug reaction), gene analysis, common variant(s) (eg, *5)	1/1/2018	10/31/2024			х	x
81331	SNRPN/UBE3A (small nuclear ribonucleoprotein polypeptide N and ubiquitin protein ligase E3A) (eg, Prader-Willi syndrome and/or Angelman syndrome), methylation analysis	2/18/2013	10/31/2024			х	
81407	MOPATH PROCEDURE LEVEL 8	1/1/2012	2/1/2024			x	
81408	MOPATH PROCEDURE LEVEL 9	1/1/2012	2/1/2024			x	

[&]quot;Cigna Companies" refers to operating subsidiaries of Cigna Corporation. All products and services are provided exclusively by or through such operating subsidiaries, including Cigna Health and Life Insurance Company, Connecticut General Life Insurance Company, Evernorth Behavioral Health, Inc., Cigna Health Management, Inc., and HMO or service company subsidiaries of Cigna Health Corporation. © 2025 Cigna.

Code	Code Description	Precert Effective Date	Precert Removal Date	ACA/IFP Precert Effective Date	Comments	Complete/PHS+ /Preferred	Basic Standard
81438*	Hereditary neuroendocrine tumor disorders (eg, medullary thyroid carcinoma, parathyroid carcinoma, malignant pheochromocytoma or paraganglioma); duplication/deletion analysis panel, must include analyses for SDHB, SDHC, SDHD, and VHL	1/1/2016	12/31/2024		Code deleted 12/31/2024	x	
81506	Endocrinology (type 2 diabetes), biochemical assays of seven analytes (glucose, HbA1c, insulin, hs-CRP, adoponectin, ferritin, interleukin 2-receptor alpha), utilizing serum or plasma, algorithm reporting a risk score	1/1/2013	10/31/2024			х	
88299	Cytogenetic Study	1/1/1900	4/12/2024			x	х
89329	Sperm evaluation; hamster penetration test	10/27/2006	10/31/2024			х	
90281	Immune globulin (Ig), human, for intramuscular use	8/19/2013	5/30/2025			х	х
90989	DIALYSIS TRAINING COMPLETE	1/26/2018	12/31/2024			х	
90993	DIALYSIS TRAINING INCOMPL	1/1/1993	12/31/2024			х	
90999	Unlisted dialysis procedure, inpatient or outpatient	1/1/1993	2/28/2025			х	
91110*	Gastrointestinal tract imaging, intraluminal (eg, capsule endoscopy), esophagus through ileum, with interpretation and report	1/1/2022	5/30/2025			x	
91111*	Gastrointestinal tract imaging, intraluminal (eg, capsule endoscopy), esophagus with interpretation and report	1/1/2022	5/30/2025			х	
91112*	Gastrointestinal transit and pressure measurement, stomach through colon, wireless capsule, with interpretation and report	1/1/2013	5/30/2025			х	
91113*	Gastrointestinal tract imaging, intraluminal (eg, capsule endoscopy), colon, with interpretation and report	1/1/2022	5/30/2025			х	
92971	Cardioassist-method of circulatory assist; external	9/15/2010	2/28/2025			x	
93350*	Echocardiography, transthoracic, real-time with image documentation (2D), includes M-mode recording, when performed, during rest and cardiovascular stress test using treadmill, bicycle exercise and/or pharmacologically induced stress, with interpretation and report;	2/17/2014	5/30/2025			x	
93351*	Echocardiography, transthoracic, real-time with image documentation (2D), includes M-mode recording, when performed, during rest and cardiovascular stress test using treadmill, bicycle exercise and/or pharmacologically induced stress, with interpretation and report; including performance of continuous electrocardiographic monitoring, with supervision by a physician or other qualified health care professional	2/17/2014	5/30/2025			х	
93583	Percutaneous transcatheter septal reduction therapy (eg, alcohol septal ablation) including temporary pacemaker insertion when performed	1/1/2017	7/25/2025			x	
93593*	Right heart catheterization for congenital heart defect(s) including imaging guidance by the proceduralist to advance the catheter to the target zone: normal native connections	1/1/2022	5/30/2025			х	
93594*	Right heart catheterization for congenital heart defect(s) including imaging guidance by the proceduralist to advance the catheter to the target zone; abnormal native connections	1/1/2022	5/30/2025			х	
93595*	Left heart catheterization for congenital heart defect(s) including imaging guidance by the proceduralist to advance the catheter to the target zone, normal or abnormal native connections	1/1/2022	5/30/2025			x	
93596*	Right and left heart catheterization for congenital heart defect(s) including imaging guidance by the proceduralist to advance the catheter to the target zone(s); normal native connections	1/1/2022	5/30/2025			x	

[&]quot;Cigna Companies" refers to operating subsidiaries of Cigna Corporation. All products and services are provided exclusively by or through such operating subsidiaries, including Cigna Health and Life Insurance Company, Connecticut General Life Insurance Company, Evernorth Behavioral Health, Inc., Cigna Health Management, Inc., and HMO or service company subsidiaries of Cigna Health Corporation. © 2025 Cigna.

Code	Code Description	Precert Effective Date	Precert Removal Date	ACA/IFP Precert Effective Date	Comments	Complete/PHS+ /Preferred	Basic Standard
93597*	Right and left heart catheterization for congenital heart defect(s) including imaging guidance by the proceduralist to advance the catheter to the target zone(s); abnormal native connections	1/1/2022	5/30/2025			x	
99500	Home visit for prenatal monitoring and assessment to include fetal heart rate, non-stress test, uterine monitoring, and gestational diabetes monitoring	10/25/2019	2/28/2025			х	
99501	Home visit for postnatal assessment and follow-up care	10/25/2019	2/28/2025			x	
99502	Home visit for newborn care and assessment	10/25/2019	2/28/2025			х	
99503	Home visit for respiratory therapy care (eg, bronchodilator, oxygen therapy, respiratory assessment, apnea evaluation)	10/25/2019	2/28/2025			х	
99504	Home visit for mechanical ventilation care	10/25/2019	2/28/2025			х	
99505	Home visit for stoma care and maintenance including colostomy and cystostomy	10/25/2019	2/28/2025			х	
99506	Home visit for intramuscular injections	10/25/2019	2/28/2025			х	
99507	Home visit for care and maintenance of catheter(s) (eg, urinary, drainage, and enteral)	10/25/2019	2/28/2025			х	
99509	Home visit for assistance with activities of daily living and personal care	10/25/2019	2/28/2025			х	
99510	Home visit for individual, family, or marriage counseling	10/25/2019	2/28/2025			х	
99511	Home visit for fecal impaction management and enema administration	10/25/2019	2/28/2025			х	
A0140	Non-emergency transportation and air travel (private or commercial) intra or inter state	1/1/2009	7/25/2025			х	
A2027	Matriderm per sq cm	10/1/2024	10/31/2024			х	
A2028	Micromatrix flex per mg	10/1/2024	10/31/2024			х	
A2029	Mirotract matrix sheet	10/1/2024	10/31/2024			х	
A4271	Integrated lancing and blood sample testing cartridges for home blood glucose monitor, per month	4/1/2024	8/30/2024			х	
A4543	Supply trans elec nerve stim	10/1/2024	10/31/2024			х	
A4544	Electro nerve stimulator rls	10/1/2024	10/31/2024			х	
A4545	Suppl accessor tibial stim	10/1/2024	10/31/2024			х	
A4641	Radiopharmaceutical, diagnostic, not otherwise classified	2/17/2017	2/28/2025			х	х
A4648	Tissue marker, implantable, any type each	8/1/2012	12/31/2024			х	
A4650	Implant radiation dosimeter, each	8/1/2012	12/31/2024			х	
A6025	Gel sheet for dermal or epidermal application, (e.g., silicone, hydrogel, other), each	4/1/2019	12/31/2024			x	
A7021	Suppl and access lung expan	10/1/2024	10/31/2024			x	
A9506	Graphite crucible for preparation of technetium to 99m-labeled carbon aerosol, one crucible	7/1/2024	2/28/2025			x	х
A9610	Xe129 xenon, diagnostic	10/1/2024	10/31/2024			x	
C1715	Brachytherapy needle	8/1/2012	12/31/2024			x	
C1716	Brachytherapy source, non-stranded, gold-198, per source	8/1/2012	12/31/2024			х	

[&]quot;Cigna Companies" refers to operating subsidiaries of Cigna Corporation. All products and services are provided exclusively by or through such operating subsidiaries, including Cigna Health and Life Insurance Company, Connecticut General Life Insurance Company, Evernorth Behavioral Health, Inc., Cigna Health Management, Inc., and HMO or service company subsidiaries of Cigna Health Corporation. © 2025 Cigna.

Code	Code Description	Precert Effective Date	Precert Removal Date	ACA/IFP Precert Effective Date	Comments	Complete/PHS+ /Preferred	Basic Standard
C1717	Brachytherapy source, non-stranded, high dose rate iridium-192, per source	8/1/2012	2/28/2025			x	
C1719	Brachytherapy source, non-stranded, non-high dose rate iridium-192, per source	8/1/2012	12/31/2024			х	
C1728	Catheter, brachytherapy seed administration	8/1/2012	12/31/2024			х	
C1761	Catheter, transluminal intravascular lithotripsy, coronary	7/1/2021	12/31/2024			х	
C2634	Brachytherapy source, non-stranded, high activity, iodine-125, greater than 1.01 mci (nist), per source	8/1/2012	12/31/2024			х	
C2635	Brachytherapy source, non-stranded, high activity, palladium-103, greater than 2.2 mci (nist), per source	8/1/2012	12/31/2024			х	
C2636	Brachytherapy linear source, non-stranded, palladium-103, per 1 mm	8/1/2012	12/31/2024			х	
C2637	Brachytherapy source, non-stranded, ytterbium-169, per source	8/1/2012	12/31/2024			х	
C2638	Brachytherapy source, stranded, iodine-125, per source	8/1/2012	12/31/2024			x	
C2639	Brachytherapy source, non-stranded, iodine-125, per source	8/1/2012	12/31/2024			x	
C2640	Brachytherapy source, stranded, palladium-103, per source	8/1/2012	12/31/2024			х	
C2641	Brachytherapy source, non-stranded, palladium-103, per source	8/1/2012	12/31/2024			х	
C2642	Brachytherapy source, stranded, cesium-131, per source	8/1/2012	12/31/2024			x	
C2643	Brachytherapy source, non-stranded, cesium-131, per source	8/1/2012	2/28/2025			х	
C2645	Brachytherapy planar source, palladium-103, per square millimeter	1/1/2016	2/28/2025			х	
C2698	Brachytherapy source, stranded, not otherwise spec	8/1/2012	12/31/2024			х	х
C2699	Brachytherapy source, non-stranded, not otherwise	8/1/2012	12/31/2024			х	x
C7504	Percutaneous vertebroplasties (bone biopsies included when performed), first cervicothoracic and any additional cervicothoracic or lumbosacral vertebral bodies, unilateral or bilateral injection, inclusive of all imaging guidance	1/1/2023	2/28/2025			x	
C7505	Percutaneous vertebroplasties (bone biopsies included when performed), first lumbosacral and any additional cervicothoracic or lumbosacral vertebral bodies, unilateral or bilateral injection, inclusive of all imaging guidance	1/1/2023	2/28/2025			x	
C7507	Percutaneous vertebral augmentations, first thoracic and any additional thoracic or lumbar vertebral bodies, including cavity creations (fracture reductions and bone biopsies included when performed) using mechanical device (eg, kyphoplasty), unilateral or bilateral cannulations, inclusive of all imaging guidance	1/1/2023	2/28/2025			x	
C7508	Percutaneous vertebral augmentations, first lumbar and any additional thoracic or lumbar vertebral bodies, including cavity creations (fracture reductions and bone biopsies included when performed) using mechanical device (eg, kyphoplasty), unilateral or bilateral cannulations, inclusive of all imaging guidance	1/1/2023	2/28/2025			x	
C7516	Catheter placement in coronary artery(s) for coronary angiography, including intraprocedural injection(s) for coronary angiography, with endoluminal imaging of initial coronary vessel or graft using intravascular ultrasound (ivus) or optical coherence tomography (oct) during diagnostic evaluation and/or therapeutic intervention including imaging supervision, interpretation and report	1/1/2023	8/30/2024			x	

[&]quot;Cigna Companies" refers to operating subsidiaries of Cigna Corporation. All products and services are provided exclusively by or through such operating subsidiaries, including Cigna Health and Life Insurance Company, Connecticut General Life Insurance Company, Evernorth Behavioral Health, Inc., Cigna Health Management, Inc., and HMO or service company subsidiaries of Cigna Health Corporation. © 2025 Cigna.

Code	Code Description	Precert Effective Date	Precert Removal Date	ACA/IFP Precert Effective Date	Comments	Complete/PHS+ /Preferred	Basic Standard
C7517	Catheter placement in coronary artery(s) for coronary angiography, including intraprocedural injection(s) for coronary angiography, with iliac and/or femoral artery angiography, non-selective, bilateral or ipsilateral to catheter insertion, performed at the same time as cardiac catheterization and/or coronary angiography, includes positioning or placement of the catheter in the distal aorta or ipsilateral femoral or iliac artery, injection of dye, production of permanent images, and radiologic supervision and interpretation	1/1/2023	8/30/2024			x	
C7518	Catheter placement in coronary artery(ies) for coronary angiography, including intraprocedural injection(s) for coronary angiography, imaging supervision and interpretation, with catheter placement(s) in bypass graft(s) (internal mammary, free arterial, venous grafts) including intraprocedural injection(s) for bypass graft angiography with endoluminal imaging of initial coronary vessel or graft using intravascular ultrasound (ivus) or optical coherence tomography (oct) during diagnostic evaluation and/or therapeutic intervention including imaging, supervision, interpretation and report	1/1/2023	8/30/2024			x	
C7519	Catheter placement in coronary artery(ies) for coronary angiography, including intraprocedural injection(s) for coronary angiography, imaging supervision and interpretation, with catheter placement(s) in bypass graft(s) (internal mammary, free arterial, venous grafts) including intraprocedural injection(s) for bypass graft angiography with intravascular doppler velocity and/or pressure derived coronary flow reserve measurement (initial coronary vessel or graft) during coronary angiography including pharmacologically induced stress	1/1/2023	8/30/2024			x	
C7520	Catheter placement in coronary artery(ies) for coronary angiography, including intraprocedural injection(s) for coronary angiography, imaging supervision and interpretation, with catheter placement(s) in bypass graft(s) (internal mammary, free arterial, venous grafts) includes intraprocedural injection(s) for bypass graft angiography with iliac and/or femoral artery angiography, non-selective, bilateral or ipsilateral to catheter insertion, performed at the same time as cardiac catheterization and/or coronary angiography, includes positioning or placement of the catheter in the distal aorta or ipsilateral femoral or iliac artery, injection of dye, production of permanent images, and radiologic supervision and interpretation	1/1/2023	8/30/2024			x	
C7521	Catheter placement in coronary artery(ies) for coronary angiography, including intraprocedural injection(s) for coronary angiography with right heart catheterization with endoluminal imaging of initial coronary vessel or graft using intravascular ultrasound (ivus) or optical coherence tomography (oct) during diagnostic evaluation and/or therapeutic intervention including imaging supervision, interpretation and report	1/1/2023	8/30/2024			x	
C7522	Catheter placement in coronary artery(ies) for coronary angiography, including intraprocedural injection(s) for coronary angiography, imaging supervision and interpretation with right heart catheterization, with intravascular doppler velocity and/or pressure derived coronary flow reserve measurement (initial coronary vessel or graft) during coronary angiography including pharmacologically induced stress	1/1/2023	8/30/2024			x	

[&]quot;Cigna Companies" refers to operating subsidiaries of Cigna Corporation. All products and services are provided exclusively by or through such operating subsidiaries, including Cigna Health and Life Insurance Company, Connecticut General Life Insurance Company, Evernorth Behavioral Health, Inc., Cigna Health Management, Inc., and HMO or service company subsidiaries of Cigna Health Corporation. © 2025 Cigna.

Code	Code Description	Precert Effective Date	Precert Removal Date	ACA/IFP Precert Effective Date	Comments	Complete/PHS+ /Preferred	Basic Standard
C7523	Catheter placement in coronary artery(ies) for coronary angiography, including intraprocedural injection(s) for coronary angiography, imaging supervision and interpretation, with left heart catheterization including intraprocedural injection(s) for left ventriculography, when performed, with endoluminal imaging of initial coronary vessel or graft using intravascular ultrasound (ivus) or optical coherence tomography (oct) during diagnostic evaluation and/or therapeutic intervention including imaging supervision, interpretation and report	1/1/2023	8/30/2024			x	
C7524	Catheter placement in coronary artery(ies) for coronary angiography, including intraprocedural injection(s) for coronary angiography, imaging supervision and interpretation, with left heart catheterization including intraprocedural injection(s) for left ventriculography, when performed, with intravascular doppler velocity and/or pressure derived coronary flow reserve measurement (initial coronary vessel or graft) during coronary angiography including pharmacologically induced stress	1/1/2023	8/30/2024			x	
C7525	Catheter placement in coronary artery(ies) for coronary angiography, including intraprocedural injection(s) for coronary angiography, imaging supervision and interpretation, with left heart catheterization including intraprocedural injection(s) for left ventriculography, when performed, catheter placement(s) in bypass graft(s) (internal mammary, free arterial, venous grafts) with bypass graft angiography with endoluminal imaging of initial coronary vessel or graft using intravascular ultrasound (ivus) or optical coherence tomography (oct) during diagnostic evaluation and/or therapeutic intervention including imaging supervision, interpretation and report	1/1/2023	8/30/2024			x	
C7526	Catheter placement in coronary artery(ies) for coronary angiography, including intraprocedural injection(s) for coronary angiography, imaging supervision and interpretation, with left heart catheterization including intraprocedural injection(s) for left ventriculography, when performed, catheter placement(s) in bypass graft(s) (internal mammary, free arterial, venous grafts) with bypass graft angiography with intravascular doppler velocity and/or pressure derived coronary flow reserve measurement (initial coronary vessel or graft) during coronary angiography including pharmacologically induced stress	1/1/2023	8/30/2024			x	
C7527	Catheter placement in coronary artery(ies) for coronary angiography, including intraprocedural injection(s) for coronary angiography, imaging supervision and interpretation, with right and left heart catheterization including intraprocedural injection(s) for left ventriculography, when performed, with endoluminal imaging of initial coronary vessel or graft using intravascular ultrasound (ivus) or optical coherence tomography (oct) during diagnostic evaluation and/or therapeutic intervention including imaging supervision, interpretation and report	1/1/2023	8/30/2024			x	

[&]quot;Cigna Companies" refers to operating subsidiaries of Cigna Corporation. All products and services are provided exclusively by or through such operating subsidiaries, including Cigna Health and Life Insurance Company, Connecticut General Life Insurance Company, Evernorth Behavioral Health, Inc., Cigna Health Management, Inc., and HMO or service company subsidiaries of Cigna Health Corporation. © 2025 Cigna.

Code	Code Description	Precert Effective Date	Precert Removal Date	ACA/IFP Precert Effective Date	Comments	Complete/PHS+ /Preferred	Basic Standard
C7528	Catheter placement in coronary artery(ies) for coronary angiography, including intraprocedural injection(s) for coronary angiography, imaging supervision and interpretation, with right and left heart catheterization including intraprocedural injection(s) for left ventriculography, when performed, with intravascular doppler velocity and/or pressure derived coronary flow reserve measurement (initial coronary vessel or graft) during coronary angiography including pharmacologically induced stress	1/1/2023	8/30/2024			x	
C7529	Catheter placement in coronary artery(ies) for coronary angiography, including intraprocedural injection(s) for coronary angiography, imaging supervision and interpretation, with right and left heart catheterization including intraprocedural injection(s) for left ventriculography, when performed, catheter placement(s) in bypass graft(s) (internal mammary, free arterial, venous grafts) with bypass graft angiography with intravascular doppler velocity and/or pressure derived coronary flow reserve measurement (initial coronary vessel or graft) during coronary angiography including pharmacologically induced stress	1/1/2023	8/30/2024			x	
C7552	Catheter placement in coronary artery(s) for coronary angiography, including intraprocedural injection(s) for coronary angiography, imaging supervision and interpretation; with catheter placement(s) in bypass graft(s) (internal mammary, free arterial, venous grafts) including intraprocedural injection(s) for bypass graft angiography and right heart catheterization with intravascular doppler velocity and/or pressure derived coronary flow reserve measurement (coronary vessel or graft) during coronary angiography including pharmacologically induced stress, initial vessel	1/1/2023	12/31/2024			x	
C7553	Catheter placement in coronary artery(s) for coronary angiography, including intraprocedural injection(s) for coronary angiography, imaging supervision and interpretation; with right and left heart catheterization including intraprocedural injection(s) for left ventriculography, when performed, catheter placement(s) in bypass graft(s) (internal mammary, free arterial, venous grafts) with bypass graft angiography with pharmacologic agent administration (eg, inhaled nitric oxide, intravenous infusion of nitroprusside, dobutamine, milrinone, or other agent) including assessing hemodynamic measurements before, during, after and repeat pharmacologic agent administration, when performed	1/1/2023	12/31/2024			x	
C8000	Suprt dev, a-v fistula, imp	10/1/2024	10/31/2024			x	
C9155	Injection, epcoritamab-bysp, 0.16 mg	10/1/2023	12/31/2023		Code deleted 12/31/2023	х	х
C9157	Injection, tofersen, 1 mg	10/1/2023	12/31/2023		Code deleted 12/31/2023	х	х
C9160	Inj daxibotulinumtoxina-lanm	1/1/2024	3/31/2024		Code deleted 3/31/2024	x	х
C9161	Inj, aflibercept hd, 1 mg	1/1/2024	3/31/2024		Code deleted 3/31/2024	x	х
C9162	Inj, avacincaptad peg 0.1 mg	1/1/2024	3/31/2024		Code deleted 3/31/2024	х	х
C9163	Inj talquetamab-tgvs 0.25 mg	1/1/2024	3/31/2024		Code deleted 3/31/2024	x	х

[&]quot;Cigna Companies" refers to operating subsidiaries of Cigna Corporation. All products and services are provided exclusively by or through such operating subsidiaries, including Cigna Health and Life Insurance Company, Connecticut General Life Insurance Company, Evernorth Behavioral Health, Inc., Cigna Health Management, Inc., and HMO or service company subsidiaries of Cigna Health Corporation. © 2025 Cigna.

Code	Code Description	Precert Effective Date	Precert Removal Date	ACA/IFP Precert Effective Date	Comments	Complete/PHS+ /Preferred	Basic Standard
C9165	Inj, elranatamab-bcmm, 1 mg	1/1/2024	3/31/2024		Code deleted 3/31/2024	х	х
C9166	Injection, secukinumab, intravenous, 1 mg	4/1/2024	6/30/2024		Code deleted 6/30/2024	x	х
C9167	Injection, adamts13, recombinant-krhn, 10 iu	4/1/2024	6/30/2024		Code deleted 6/30/2024	х	х
C9168	Injection, mirikizumab-mrkz, 1 mg	4/1/2024	6/30/2024		Code deleted 6/30/2024	х	х
C9169*	Inj, nogapendekin pmln 1 mcg	10/1/2024	12/31/2024		Code deleted 12/31/2024	х	х
C9170*	Inj, tarlatamab-dlle, 1 mg	10/1/2024	12/31/2024		Code deleted 12/31/2024	х	х
C9172	Inj, beqvez, per tx dose	10/1/2024	12/31/2024		Code deleted 12/31/2024	х	х
C9173*	Injection, filgrastim-txid (nypozi), biosimilar, 1 microgram	1/1/2025	6/30/2025		Code deleted 6/30/2025. EviCore Medical Oncology Program for oncology diagnoses. Cigna managed for non-oncology indications.	х	x
C9174*	Injection, datopotamab deruxtecan-dlnk, 1 mg	7/1/2025	9/30/2025		Code deleted 9/30/2025	x	х
C9175*	Injection, treosulfan, 50 mg	7/1/2025	9/30/2025		Code deleted 9/30/2025	х	x
C9301	Obecabtagene autoleucel, up to 410 million cd19 car-positive viable t cells, including leukapheresis and dose preparation procedures, per therapeutic dose	4/1/2025	6/30/2025		Code deleted 6/30/2025	х	x
C9302*	Injection, zanidatamab-hrii, 2 mg	4/1/2025	6/30/2025		Code deleted 6/30/2025	x	x
C9303*	Injection, zolbetuximab-clzb, 1 mg	4/1/2025	6/30/2025		Code deleted 6/30/2025	x	х
C9304	Injection, marstacimab-hncq, 0.5 mg	4/1/2025	6/30/2025		Code deleted 6/30/2025	х	х
C9725	Placement ofÿendorectal intracavitary applicator for high intensity brachytherapy	8/1/2012	12/31/2024			х	
C9728	Placement of interstitial device(s) for radiation therapy/surgery guidance (e.g., fiducial markers, dosimeter), for other than the following sites (any approach): abdomen, pelvis, prostate, retroperitoneum, thorax, single or multiple	8/1/2012	12/31/2024			x	
C9771	Nasal/sinus endoscopy, cryoablation nasal tissue(s) and/or nerve(s), unilateral or bilateral	1/1/2021	12/31/2023		Code deleted 12/31/2023	х	
C9777*	Esophageal mucosal integrity testing by electrical impedance, transoral, includes esophagoscopy or esophagogastroduodenoscopy	1/28/2022	8/30/2024			х	
C9781	Arthroscopy, shoulder, surgical; with implantation of subacromial spacer (e.g., balloon), includes debridement (e.g., limited or extensive), subacromial decompression, acromioplasty, and biceps tenodesis when performed	4/1/2022	10/31/2024			х	х
C9796	Repair of enterocutaneous fistula small intestine or colon (excluding anorectal fistula) with plug (e.g., porcine small intestine submucosa [sis])	4/1/2024	2/28/2025			х	
D7880	occlusal orthotic device, by report	1/1/2001	7/25/2025			x	
D7881	occlusal orthotic device adjustment	1/1/2016	2/28/2025			х	
E0469	Lung expans high oscil neb	10/1/2024	10/31/2024			х	
E0656	Segmental pneumatic appliance for use with pneumatic compressor, trunk	1/1/2009	8/30/2024			х	
E0657	Segmental pneumatic appliance for use with pneumatic compressor, chest	1/1/2009	8/30/2024			х	
E0670	Segmental pneumatic appliance for use with pneumatic compressor, integrated, 2 full legs and trunk	1/1/2013	8/30/2024			х	
E0715	Intravag pelvic floor kegel	10/1/2024	10/31/2024			х	

[&]quot;Cigna Companies" refers to operating subsidiaries of Cigna Corporation. All products and services are provided exclusively by or through such operating subsidiaries, including Cigna Health and Life Insurance Company, Connecticut General Life Insurance Company, Evernorth Behavioral Health, Inc., Cigna Health Management, Inc., and HMO or service company subsidiaries of Cigna Health Corporation. © 2025 Cigna.

Code	Code Description	Precert Effective Date	Precert Removal Date	ACA/IFP Precert Effective Date	Comments	Complete/PHS+ /Preferred	Basic Standard
E0716	Supp and acces intravag pelv	10/1/2024	10/31/2024			x	
E0736	Transcutaneous tibial nerve stimulator	4/1/2024	10/17/2025			х	
E0737	Transcut tibial stim by app	10/1/2024	10/31/2024			x	
E0743	Ext low ext nerve stimu rls	10/1/2024	10/31/2024			x	
E1005	Wheelchair accessory, power seating system, recline only, with power shear reduction	1/22/2007	12/1/2023			x	
E1006	Wheelchair accessory, power seating system, combination tilt and recline, without shear reduction	1/22/2007	12/1/2023			х	
E1009	Wheelchair accessory, addition to power seating system, mechanically linked leg elevation system, including pushrod and leg rest, each	1/22/2007	12/1/2023			х	
E1230	Power operated vehicle (three or four wheel nonhighway) specify brand name and model number	10/1/2006	12/1/2023			х	
E2104	Home blood glucose monitor for use with integrated lancing/blood sample testing cartridge	4/1/2024	8/30/2024			х	
E2300	Power wheelchair accessory, power seat elevation system	10/1/2006	12/1/2023		Code deleted 3/31/2024	х	
E2513	Sgd accessory, emg sensor	10/1/2024	10/31/2024			х	
G0051	Patients under hospice care in the current reporting month	1/1/2022	2/28/2025			х	
G0155	Services of clinical social worker in home health or hospice settings, each 15 minutes	10/25/2019	7/25/2025			x	
G0156	Services of home health/hospice aide in home health or hospice settings, each 15 minutes	10/25/2019	7/25/2025			х	
G0299	Direct skilled nursing services of a registered nurse (rn) in the home health or hospice setting, each 15 minutes	10/25/2019	7/25/2025			х	
G0300	Direct skilled nursing services of a licensed practical nurse (lpn) in the home health or hospice setting, each 15 minutes	10/25/2019	7/25/2025			х	
G0337	Hospice evaluation and counseling services, pre-election	1/1/2005	7/25/2025			х	
G0493	Skilled services of a registered nurse (rn) for the observation and assessment of the patient's condition, each 15 minutes (the change in the patient's condition requires skilled nursing personnel to identify and evaluate the patient's need for possible modification of treatment in the home health or hospice setting)	1/1/2017	7/25/2025			x	
G0494	Skilled services of a licensed practical nurse (Ipn) for the observation and assessment of the patient's condition, each 15 minutes (the change in the patient's condition requires skilled nursing personnel to identify and evaluate the patient's need for possible modification of treatment in the home health or hospice setting)	1/1/2017	7/25/2025			x	
G0564	Creation of subcutaneous pocket with insertion of 365 day implantable interstitial glucose sensor, including system activation and patient training	1/1/2025	3/31/2025		Code deleted 3/31/2025	х	x
G9012	Other specified case management service not elsewhere classified	2/17/2017	12/31/2024			х	
G9687	Hospice services provided to patient any time during the measurement period	1/1/2017	2/28/2025			х	
G9690	Patient receiving hospice services any time during the measurement period	1/1/2019	2/28/2025			х	
G9720	Hospice services for patient occurred any time during the measurement period	1/1/2017	2/28/2025			х	
G9758	Patient in hospice at any time during the measurement period	1/1/2018	2/28/2025			х	
G9858	Patient enrolled in hospice	1/1/2017	2/28/2025			х	

[&]quot;Cigna Companies" refers to operating subsidiaries of Cigna Corporation. All products and services are provided exclusively by or through such operating subsidiaries, including Cigna Health and Life Insurance Company, Connecticut General Life Insurance Company, Evernorth Behavioral Health, Inc., Cigna Health Management, Inc., and HMO or service company subsidiaries of Cigna Health Corporation. © 2025 Cigna.

Code	Code Description	Precert Effective Date	Precert Removal Date	ACA/IFP Precert Effective Date	Comments	Complete/PHS+ /Preferred	Basic Standard
G9860	Patient spent less than three days in hospice care	1/1/2017	2/28/2025			х	
G9861	Patient spent greater than or equal to three days in hospice care	1/1/2017	2/28/2025			х	
H0008	Alc/Dru Subac Det-Hos Ip	1/1/2001	12/31/2024			х	х
H0009	Alc/Drug Ac Detox-Hos Ip	1/1/2001	12/31/2024			x	х
H0031	Mental health assessment, by non-physician	8/26/2016	12/31/2024			x	
H0032	Mental health service plan development by non-physician	8/26/2016	12/31/2024			х	
H0035	Mental health partial hospitalization, treatment, less than 24 hours	8/27/2015	12/31/2024			х	
H0046	Mental health services, not otherwise specified	2/17/2017	4/25/2025			x	
H2012	Behavioral health day treatment, per hour	8/26/2016	12/31/2024			x	
H2016	Comprehensive community support services, per diem	2/17/2017	12/31/2024			х	
H2019	Therapeutic behavioral services, per 15 minutes	8/26/2016	4/25/2025			х	
J0135	Injection, Adalimumab, 20 mg	1/1/2005	12/31/2024		Code deleted 12/31/2024	х	х
J0185*	Injection, aprepitant, 1 mg	1/1/2019	5/30/2025			х	х
J1300	Injection, eculizumab, 10 mg	5/1/2011	3/31/2025		Code deleted 3/31/2025	х	х
J1434*	Injection, fosaprepitant (focinvez), 1 mg	4/1/2024	5/30/2025			x	х
J1453*	Injection, fosaprepitant, 1 mg - Brand name: EMEND	1/1/2018	5/30/2025			x	х
J1454*	Injection, fosnetupitant 235 mg and palonosetron 0.25 mg	1/1/2019	5/30/2025			x	х
J1456*	Injection, fosaprepitant (teva), not therapeutically equivalent to j1453, 1 mg	1/1/2023	5/30/2025			x	х
J1627*	Injection, granisetron, extended-release, 0.1 mg	1/1/2018	5/30/2025			х	х
J1749	Inj, iloprost, 0.1 mcg	10/1/2024	12/31/2024			x	x
J2403	Chloroprocaine hcl ophthalmic, 3% gel, 1 mg	4/28/2023	5/31/2024			x	x
J2468*	Injection, palonosetron hydrochloride (avyxa), not therapeutically equivalent to j2469, 25 micrograms	7/1/2024	5/30/2025			x	х
J2469*	Injection, palonosetron hcl, 25 mcg	1/1/2018	5/30/2025			х	х
J2503	Injection, pegaptanib sodium, 0.3 mg	8/6/2012	9/30/2025		Code deleted 9/30/2025	х	х
J2796	Injection, romiplostim, 10 mcg	1/1/2010	12/31/2024		Code deleted 12/31/2024	х	х
J7799	Noc drugs, other than inhalation drugs, administered through dme	8/27/2009	9/12/2025			х	х
J9037*	Injection, belantamab mafodotin-blmf, 0.5 mg	4/1/2021	3/31/2025		Code deleted 3/31/2025	х	х
J9058*	Injection, bendamustine hydrochloride (apotex), 1 mg	7/1/2023	12/31/2024		Code deleted 12/31/2024	x	х
J9059*	Injection, bendamustine hydrochloride (baxter), 1 mg	7/1/2023	12/31/2024		Code deleted 12/31/2024	х	х
J9247*	Injection, melphalan flufenamide, 1mg	10/1/2021	3/31/2025		Code deleted 3/31/2025	x	х
J9258*	Injection, paclitaxel protein-bound particles (teva) not therapeutically equivalent to J9264, 1 mg	1/1/2024	9/30/2024		Code deleted 9/30/2024	х	х

[&]quot;Cigna Companies" refers to operating subsidiaries of Cigna Corporation. All products and services are provided exclusively by or through such operating subsidiaries, including Cigna Health and Life Insurance Company, Connecticut General Life Insurance Company, Evernorth Behavioral Health, Inc., Cigna Health Management, Inc., and HMO or service company subsidiaries of Cigna Health Corporation. © 2025 Cigna.

Code	Code Description	Precert Effective Date	Precert Removal Date	ACA/IFP Precert Effective Date	Comments	Complete/PHS+ /Preferred	Basic Standard
J9259*	Injection, paclitaxel protein-bound particles (american regent) not therapeutically equivalent to J9264, 1 mg	7/1/2023	12/31/2024		Code deleted 12/31/2024	x	х
J9340*	Injection, thiotepa, 15 mg - Brand name: THIOTEPA	1/1/2018	6/30/2025		Code deleted 6/30/2025	х	х
J9371*	Injection, Vincristine Sulfate Liposome, 1MG	1/1/2014	6/30/2024		Code deleted 6/30/2024	х	х
K0808	Power operated vehicle, group 2 very heavy duty, patient weight capacity 451 to 600 pounds	10/27/2006	12/1/2023			х	
K0814	Power wheelchair, group 1 standard, portable, captains chair, patient weight capacity up to and including 300 pounds	10/27/2006	12/1/2023			х	
K0823	Power wheelchair, group 2 standard, captains chair, patient weight capacity up to and including 300 pounds	10/27/2006	12/1/2023			х	
K0842	Power wheelchair, group 2 standard, multiple power option, captains chair, patient weight capacity up to and including 300 pounds	10/27/2006	12/1/2023			х	
K0848	Power wheelchair, group 3 standard, sling/solid seat/back, patient weight capacity up to and including 300 pounds	10/27/2006	12/1/2023			х	
K0852	Power wheelchair, group 3 very heavy duty, sling/solid seat/back, patient weight capacity 451 to 600 pounds	10/27/2006	12/1/2023			х	
K0857	Power wheelchair, group 3 standard, single power option, captains chair, patient weight capacity up to and including 300 pounds	10/27/2006	12/1/2023			х	
K0862	Power wheelchair, group 3 heavy duty, multiple power option, sling/solid seat/back, patient weight capacity 301 to 450 pounds	10/27/2006	12/1/2023			x	
K0886	Power wheelchair, group 4 heavy duty, multiple power option, sling/solid seat/back, patient weight capacity 301 to 450 pounds	10/27/2006	12/1/2023			х	
K1001	Electronic positional obstructive sleep apnea treatment, with sensor, includes all components and accessories, any type	1/1/2020	12/31/2023		Code deleted 12/31/2023	х	
K1024	Non-pneumatic compression controller with sequential calibrated gradient pressure	10/1/2021	12/31/2023		Code deleted 12/31/2023	х	
K1025	Non-pneumatic sequential compression garment, full arm	10/1/2021	12/31/2023		Code deleted 12/31/2023	x	
K1028*	Power source and control electronics unit for oral device/appliance for neuromuscular electrical stimulation of the tongue muscle for the reduction of snoring and obstructive sleep apnea, controlled by phone application	4/1/2022	12/31/2023		Code deleted 12/31/2023	x	
K1032	Non-pneumatic sequential compression garment, full leg	4/1/2022	12/31/2023		Code deleted 12/31/2023	х	х
K1033	Non-pneumatic sequential compression garment, half leg	4/1/2022	12/31/2023		Code deleted 12/31/2023	х	х
K1035	Molecular diagnostic test reader, nonprescription self-administered and self-collected use, fda approved, authorized or cleared	4/28/2023	2/28/2025			x	
L1006	Scoliosis orth sag/ cor	10/1/2024	10/31/2024			x	
L1653	Ho abduction static ots	10/1/2024	10/31/2024			х	
L1821	Ko elas w/ condyle pads otf	10/1/2024	10/31/2024			х	
L8720	Ext low ext sens prosthe mec	10/1/2024	10/31/2024			x	
L8721	Receptor sole I8720 replace	10/1/2024	10/31/2024			x	
P9027	Rbc o2 co2 reduced	10/1/2024	10/31/2024			x	
Q0519	Supply fee hiv prep inj 30	9/15/2024	10/31/2024		Code deleted 12/31/2024	x	
Q0520	Supply fee hiv prep inj 60	9/15/2024	10/31/2024		Code deleted 12/31/2024	х	
Q4082	Drug or biological, not otherwise classified, part b drug competitive acquisition program (cap)	1/1/2007	3/28/2025			х	х

[&]quot;Cigna Companies" refers to operating subsidiaries of Cigna Corporation. All products and services are provided exclusively by or through such operating subsidiaries, including Cigna Health and Life Insurance Company, Connecticut General Life Insurance Company, Evernorth Behavioral Health, Inc., Cigna Health Management, Inc., and HMO or service company subsidiaries of Cigna Health Corporation. © 2025 Cigna.

Code	Code Description	Precert Effective Date	Precert Removal Date	ACA/IFP Precert Effective Date	Comments	Complete/PHS+ /Preferred	Basic Standard
Q4107	Graftjacket, per square centimeter	1/1/2009	4/25/2025			х	х
Q4110	Primatrix, per square centimeter	1/1/2009	4/25/2025			х	x
Q4121	Theraskin, per square centimeter	2/6/2012	4/25/2025			х	x
Q4210	Axolotl graft or axolotl dualgraft, per square centimeter	10/1/2019	6/30/2024		Code deleted 6/30/2024	х	x
Q4334	Amnioplast 1, per sq cm	10/1/2024	10/31/2024			х	
Q4335	Amnioplast 2, per sq cm	10/1/2024	10/31/2024			х	
Q4336	Artecent c, per sq cm	10/1/2024	10/31/2024			х	
Q4337	Artecent trident, per sq cm	10/1/2024	10/31/2024			х	
Q4338	Artacent velos, per sq cm	10/1/2024	10/31/2024			х	
Q4339	Artacent vericlen, per sq cm	10/1/2024	10/31/2024			х	
Q4340	Simpligraft, per sq cm	10/1/2024	10/31/2024			х	
Q4341	Simplimax, per sq cm	10/1/2024	10/31/2024			х	
Q4342	Theramend, per sq cm	10/1/2024	10/31/2024			х	
Q4343	Dermacyte ac matrx per sq cm	10/1/2024	10/31/2024			х	
Q4344	Tri membrane wrap, per sq cm	10/1/2024	10/31/2024			х	
Q5001	Hospice or home health care provided in patient's home/residence	2/16/2015	7/25/2025			х	
Q5002	Hospice or home health care provided in assisted living facility	2/16/2015	7/25/2025			х	
Q5003	Hospice care provided in nursing long term care facility (Itc) or non- skilled nursing facility (nf)	2/16/2015	7/25/2025			x	
Q5009	Hospice or home health care provided in place not otherwise specified (nos)	2/16/2015	7/25/2025			х	
Q5010	Hospice home care provided in a hospice facility	10/1/2010	7/25/2025			х	
Q5131	Injection, adalimumab-aacf (idacio), biosimilar, 20 mg	7/1/2023	12/31/2024		Code deleted 12/31/2024	x	х
Q5132	Injection, adalimumab-afzb (abrilada), biosimilar, 10 mg	1/1/2024	12/31/2024		Code deleted 12/31/2024	х	x
Q5139	Injection, eculizumab-aeeb (bkemv), biosimilar, 10 mg	1/1/2025	3/31/2025		Code deleted 3/31/2025	х	х
S0148*	Injection, pegylated interferon alfa-2b, 10 mcg	10/1/2010	6/27/2025		EviCore Medical Oncology Program for oncology diagnoses. Cigna managed for non-oncology indications.	х	х
S0201	Partial hospitalization services, less than 24 hours, per diem	8/27/2015	12/31/2024			x	
S0255	Hospice referral visit (advising patient and family of care options) performed by nurse, social worker, or other designated staff	1/1/2002	7/25/2025			x	
S0271	Physician management of patient home care, hospice monthly case rate (per 30 days)	4/1/2007	2/28/2025			x	
S2103	Adrenal tissue transplant to brain	1/1/2001	10/31/2024			х	
S8035	Magnetic source imaging	1/1/2000	8/30/2024			х	
S9126	Hospice care, in the home, per diem	2/16/2015	7/25/2025			х	
S9127	Social work visit, in the home, per diem	10/25/2019	2/28/2025			х	

[&]quot;Cigna Companies" refers to operating subsidiaries of Cigna Corporation. All products and services are provided exclusively by or through such operating subsidiaries, including Cigna Health and Life Insurance Company, Connecticut General Life Insurance Company, Evernorth Behavioral Health, Inc., Cigna Health Management, Inc., and HMO or service company subsidiaries of Cigna Health Corporation. © 2025 Cigna.

Code	Code Description	Precert Effective Date	Precert Removal Date	ACA/IFP Precert Effective Date	Comments	Complete/PHS+ /Preferred	Basic Standard
S9325	Home infusion therapy, pain management infusion; administrative services, professional pharmacy services, care coordination, and all necessary supplies and equipment, per diem	1/1/2002	2/28/2025			x	х
S9326	Home infusion therapy, continuous (twenty-four hours or more) pain management infusion; administrative services, professional pharmacy services, care coordination and all necessary supplies and equipment, per diem	1/1/2002	2/28/2025			х	х
S9327	Home infusion therapy, intermittent (less than twenty-four hours) pain management infusion; administrative services, professional pharmacy services, care coordination, and all necessary supplies and equipment, per diem	1/1/2002	2/28/2025			x	х
S9328	Home infusion therapy, implanted pump pain management infusion; administrative services, professional pharmacy services, care coordination, and all necessary supplies and equipment, per diem	1/1/2002	2/28/2025			x	x
S9336	Home infusion therapy, continuous anticoagulant infusion therapy (e.g., heparin), administrative services, professional pharmacy services, care coordination and all necessary supplies and equipment, per diem	1/1/2002	2/28/2025			x	x
S9340	Home therapy; enteral nutrition; administrative services, professional pharmacy services, care coordination, and all necessary supplies and equipment, per diem	1/1/2002	2/28/2025			х	х
S9342	Home therapy; enteral nutrition via pump; administrative services, professional pharmacy services, care coordination, and all necessary supplies and equipment, per diem	1/1/2002	2/28/2025			x	х
S9343	Home therapy; enteral nutrition via bolus; administrative services, professional pharmacy services, care coordination, and all necessary supplies and equipment, per diem	1/1/2002	2/28/2025			x	x
S9346	Home infusion therapy, alpha-1-proteinase inhibitor (e.g., prolastin); administrative services, professional pharmacy services, care coordination, and all necessary supplies and equipment, per diem	1/1/2002	2/28/2025			х	х
S9347	Home infusion therapy, uninterrupted, long-term, controlled rate intravenous or subcutaneous infusion therapy (e.g., epoprostenol); administrative services, professional pharmacy services, care coordination, and all necessary supplies and equipment, per diem	1/1/2002	2/28/2025			x	x
S9348	Home infusion therapy, sympathomimetic/inotropic agent infusion therapy (e.g., dobutamine); administrative services, professional pharmacy services, care coordination, all necessary supplies and equipment, per diem	1/1/2002	2/28/2025			х	х
S9351	Home infusion therapy, continuous or intermittent anti-emetic infusion therapy; administrative services, professional pharmacy services, care coordination, and all necessary supplies and equipment, per diem	1/1/2002	2/28/2025			x	x
S9353	Home infusion therapy, continuous insulin infusion therapy; administrative services, professional pharmacy services, care coordination, and all necessary supplies and equipment, per diem	1/1/2002	2/28/2025			x	x
S9355	Home infusion therapy, chelation therapy; administrative services, professional pharmacy services, care coordination, and all necessary supplies and equipment, per diem	1/1/2002	3/28/2025			х	x
S9357	Home infusion therapy, enzyme replacement intravenous therapy; (e.g., imiglucerase); administrative services, professional pharmacy services, care coordination, and all necessary supplies and equipment, per diem	1/1/2002	2/28/2025			x	х
S9359	Home infusion therapy, anti-tumor necrosis factor intravenous therapy; (e.g., infliximab); administrative services, professional pharmacy services, care coordination, and all necessary supplies and equipment, per diem	1/1/2002	2/28/2025			x	x

Code	Code Description	Precert Effective Date	Precert Removal Date	ACA/IFP Precert Effective Date	Comments	Complete/PHS+ /Preferred	Basic Standard
S9361	Home infusion therapy, diuretic intravenous therapy; administrative services, professional pharmacy services, care coordination, and all necessary supplies and equipment, per diem	1/1/2002	2/28/2025			x	x
S9363	Home infusion therapy, anti-spasmotic therapy; administrative services, professional pharmacy services, care coordination, and all necessary supplies and equipment, per diem	1/1/2002	2/28/2025			х	х
S9364	Home infusion therapy, total parenteral nutrition (tpn); administrative services, professional pharmacy services, care coordination, and all necessary supplies and equipment including standard tpn formula, per diem	1/1/2002	2/28/2025			x	x
S9365	Home infusion therapy, total parenteral nutrition (tpn); one liter per day, administrative services, professional pharmacy services, care coordination, and all necessary supplies and equipment including standard tpn formula, per diem	1/1/2002	2/28/2025			х	x
S9366	Home infusion therapy, total parenteral nutrition (tpn); more than one liter but no more than two liters per day, administrative services, professional pharmacy services, care coordination, and all necessary supplies and equipment including standard tpn formula, per diem	1/1/2002	2/28/2025			x	x
S9367	Home infusion therapy, total parenteral nutrition (tpn); more than two liters but no more than three liters per day, administrative services, professional pharmacy services, care coordination, and all necessary supplies and equipment including standard tpn formula, per diem	1/1/2002	2/28/2025			x	х
S9368	Home infusion therapy, total parenteral nutrition (tpn); more than three liters per day, administrative services, professional pharmacy services, care coordination, and all necessary supplies and equipment including standard tpn formula, per diem	1/1/2002	2/28/2025			x	x
S9370	Home therapy, intermittent anti-emetic injection therapy; administrative services, professional pharmacy services, care coordination, and all necessary supplies and equipment, per diem	1/1/2002	2/28/2025			x	x
S9372	Home therapy; intermittent anticoagulant injection therapy (e.g., heparin); administrative services, professional pharmacy services, care coordination, and all necessary supplies and equipment, per diem	1/1/2002	2/28/2025			x	x
S9379	Home infusion therapy, infusion therapy, not otherwise classified; administrative services, professional pharmacy services, care coordination, and all necessary supplies and equipment, per diem	1/1/2002	2/28/2025			х	х
S9563	Home injectable therapy, immunotherapy, including administrative services, professional pharmacy services, care coordination, and all necessary supplies and equipment, per diem	4/28/2023	2/28/2025			х	х
S9975	Transplant related lodging, meals and transportation, per diem	4/1/2002	10/17/2025			х	х
T2042	Hospice routine home care; per diem	10/1/2003	2/28/2025			x	
T2043	Hospice continuous home care; per hour	10/1/2003	2/28/2025			х	

[&]quot;Cigna Companies" refers to operating subsidiaries of Cigna Corporation. All products and services are provided exclusively by or through such operating subsidiaries, including Cigna Health and Life Insurance Company, Connecticut General Life Insurance Company, Evernorth Behavioral Health, Inc., Cigna Health Management, Inc., and HMO or service company subsidiaries of Cigna Health Corporation. © 2025 Cigna.